INmune Bio and Quantum Computing Inc. have partnered to utilize the Dirac-3S quantum optimization machine to identify new therapeutic indications and biomarkers for the drug candidate XPro.
Key Points
- INmune Bio will use QCi’s Dirac-3S quantum machine to analyze clinical data from four trials of its investigational Alzheimer’s treatment, XPro.
- The collaboration aims to identify new disease targets for XPro, specifically focusing on rare diseases that may allow for faster, more capital-efficient clinical trials.
- This agreement marks QCi’s first commercial entry into the pharmaceutical and biotechnology sectors.
- Researchers will compare quantum optimization results against conventional machine-learning methods to evaluate the effectiveness of quantum computing in drug development.
- The project seeks to establish a repeatable discovery process for identifying patient populations and biomarkers that predict positive treatment responses.